The semaglutide shortage 2026 picture is simpler than most coverage suggests: the shortage is officially over, compounded GLP-1 remains available through licensed clinics, and prices have risen from their 2023–2024 lows — but remain far below branded Wegovy.
By Alexandru Vieru | Independently researched | Published July 2026. Regulatory data verified: June 2026.
The quick answer: The FDA officially removed semaglutide from its Drug Shortages Database in early February 2025. Tirzepatide came off the list in October 2024. Both branded medications — Wegovy and Zepbound — are widely available at US pharmacies in 2026. Compounded semaglutide and tirzepatide remain accessible through licensed 503A telehealth clinics at $133–$299/month. The semaglutide shortage 2026 situation is not a supply crisis — it is a regulatory transition — and knowing which compounding pathway your clinic uses determines your access and legal certainty.
Semaglutide Shortage 2026: When Did It Officially End?
The FDA maintains an official Drug Shortages Database that determines which drugs can be compounded at large scale by federally registered 503B outsourcing facilities.
- Tirzepatide (Zepbound / Mounjaro): Removed from the FDA shortage list in October 2024.
- Semaglutide (Wegovy / Ozempic): Removed from the FDA shortage list in early February 2025.
The shortage designation ending was a rolling determination, not a single announcement. Novo Nordisk and Eli Lilly submitted supply adequacy data showing they could meet national demand for their FDA-approved branded products. The FDA agreed and updated the shortage designation accordingly.
For the millions of patients who turned to compounded GLP-1 medication during 2022–2024 — when Wegovy and Mounjaro were genuinely hard to find — this shift carried significant implications that unfolded over months. Understanding those implications is exactly what the semaglutide shortage 2026 question is really asking.
What the Shortage Ending Triggered: A Regulatory Cascade
The shortage designation is not just a label. Under the Drug Quality and Security Act, 503B outsourcing facilities — large-scale, federally registered compounders — may only compound drugs from bulk active pharmaceutical ingredients when those drugs appear on the FDA's drug shortage list or on a separately maintained bulk substances list. Semaglutide and tirzepatide were never approved for that bulk substances list; they were compoundable at industrial scale only because of the shortage designation.
When the shortage ended, the 503B legal basis for mass-market GLP-1 compounding evaporated. The regulatory cascade that followed shaped the semaglutide shortage 2026 landscape buyers are navigating today:
- October–November 2024: FDA issues tirzepatide wind-down guidance for 503B facilities, citing the October shortage resolution.
- February–March 2025: FDA declares semaglutide shortage resolved; enforcement guidance issued directing 503B facilities to wind down semaglutide compounding.
- Throughout 2025: Active FDA enforcement — warning letters, consent decrees, inspections — targeting 503B facilities continuing large-scale GLP-1 production despite guidance.
- April 30, 2026: FDA publishes a Notice of Proposed Rulemaking to formally and permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk compoundable substances list.
- June 29, 2026: Public comment period on the proposed rule closes. Final rule expected in late 2027 at the earliest.
For the full legal background on what the proposed rule does and does not target, see our compounded semaglutide legal analysis and the post-comment-deadline update.
Is Compounded Semaglutide Still Available in 2026?
Yes — through the correct legal pathway. This is the core question behind most semaglutide shortage 2026 searches, and the answer turns on understanding two distinct compounding frameworks under US law.
503B outsourcing facilities needed the shortage designation to compound GLP-1 at industrial scale. When the shortage ended, that legal basis evaporated. Most legitimate 503B facilities have dramatically curtailed or halted GLP-1 production since early 2025. This is the segment of the market that contracted.
503A compounding pharmacies — state-licensed traditional pharmacies that prepare medication for individual patients under a patient-specific prescription from a licensed clinician — operate on a completely separate legal foundation. They have never needed a drug shortage designation or a federal bulks list. They have existed long before GLP-1 medications existed. The FDA's 2025–2026 enforcement campaign targeted 503B industrial operators; it did not change the 503A legal framework.
The telehealth model used by reputable online GLP-1 clinics works entirely through the 503A pathway:
- You complete a telehealth evaluation with a licensed clinician.
- The clinician reviews your medical history, BMI, and GLP-1 eligibility.
- A patient-specific prescription is written documenting your individual clinical need.
- A licensed 503A compounding pharmacy fills that prescription for you specifically.
This model has operated continuously throughout the entire semaglutide shortage 2026 regulatory transition and is available in all 50 states in 2026.
| 503A Traditional Pharmacy | 503B Outsourcing Facility | |
|---|---|---|
| Regulated by | State pharmacy board | FDA (federal registration) |
| Patient-specific Rx required | Yes — always | Not required |
| Needed shortage designation? | No | Yes, for bulk API |
| Status in 2026 | Continues operating | GLP-1 largely wound down |
What Changed for GLP-1 Pricing After the Shortage
The semaglutide shortage 2026 market looks meaningfully different from the 2023–2024 peak, primarily on price. During the shortage period, 503B facilities producing at industrial scale briefly drove compounded semaglutide below $100/month in some markets. Those economics reflected mass production volumes that are no longer legally available. With the 503B segment wound down, licensed 503A compounding pharmacies operating at individual-prescription scale set current pricing:
| Route | Medication | Price Range | Representative Clinics |
|---|---|---|---|
| Compounded 503A telehealth | Semaglutide injection | $133–$199/mo | Oak $133, Yucca $146, Wellorithm $147 |
| Compounded 503A telehealth | Semaglutide oral / sublingual | $147–$199/mo | Direct Meds $147, others $199+ |
| Compounded 503A telehealth | Tirzepatide injection | $199–$299/mo | Most licensed clinics |
| Brand-name (commercially insured) | Wegovy | As low as $25/mo | With Novo Nordisk savings card |
| Brand-name (cash, no insurance) | Wegovy | ~$1,349/mo | Without coverage |
| Brand-name cash (Lilly Direct) | Zepbound single-dose vials | From $399/mo | Via lilydirect.com |
Compounded options through licensed 503A telehealth clinics remain significantly more affordable than branded alternatives for uninsured patients. The gap — $133–$299/month versus $1,349/month cash for Wegovy — has narrowed from the 2024 bottom but is still enormous. For a full breakdown including insurance calculations, see our 2026 GLP-1 cost guide.
Needle-free formats have also expanded significantly since the shortage era. Multiple licensed 503A clinics now offer oral, sublingual, and gum-based semaglutide as part of their programs. Our guide to oral and needle-free GLP-1 programs compares what is available and where.
Brand-Name Wegovy and Zepbound Are More Accessible Now
One underappreciated upside of the semaglutide shortage 2026 resolution: branded GLP-1 medications are genuinely accessible in ways they were not in 2022 or 2023.
Wegovy (semaglutide, Novo Nordisk): Available at major retail pharmacies nationwide. For commercially insured patients with qualifying plans, Novo Nordisk's savings program can reduce out-of-pocket cost to $0–$25/month. Without insurance, the current cash price runs approximately $1,349/month for standard maintenance doses.
Zepbound (tirzepatide, Eli Lilly): Eli Lilly's single-dose vials — sold direct through Lilly Direct — introduced a cash-pay pathway at $399/month for 2.5 mg starter doses and $549/month for 5 mg and above. These are FDA-approved branded doses, not compounded. For patients who want the regulatory certainty of a licensed brand-name product, Zepbound via Lilly Direct is now a real option.
Wellorithm is the only clinic in our rankings that bridges both worlds: compounded semaglutide from $147/month and same-platform access to brand-name Wegovy, Ozempic, Mounjaro, and Zepbound for patients who want or eventually need the branded version. That optionality is exactly why it earns our "Best Brand Access" pick.
What GLP-1 Buyers Should Know in 2026
The semaglutide shortage 2026 picture is genuinely encouraging for patients — with important nuances:
Access is broad. Compounded semaglutide and tirzepatide through licensed telehealth clinics with 503A pharmacy partners is available in all 50 states. Branded Wegovy and Zepbound are at pharmacies nationwide. The genuine supply crisis of 2022–2023 is resolved.
The legal pathway matters more now. During the shortage, the FDA tolerated a wide range of compounding models out of necessity. In 2026, the clear standard is: patient-specific prescription from a licensed clinician, filled by a licensed 503A pharmacy. Clinics using this model are on solid legal footing; others face growing enforcement risk.
Gray-market risk persists. The FDA's enforcement campaign shut down many of the most egregious unlicensed sources but not all of them. The 455+ adverse event reports linked to compounded semaglutide as of early 2025 were concentrated in this gray market — dosing errors from unlabeled multi-dose vials, incorrect concentrations, no clinical oversight. Sourcing GLP-1 without a licensed clinician evaluation and valid prescription remains the highest-risk segment of this market.
Quality matters more than the lowest price. The cheapest 2023 options included many 503B-adjacent gray-market sources that no longer operate. Today's licensed 503A clinics start at $133/month — not $79 — but they come with licensed prescribers, certified pharmacy partners, and documented clinical intake.
Top-Rated Clinics Using Licensed 503A Models (All 50 States)
All clinics in our independent GLP-1 rankings work with licensed 503A compounding pharmacy partners and require a licensed-clinician prescription for each patient. Commission does not influence these scores.
| Clinic | Score | Starting Price | Why It Stands Out |
|---|---|---|---|
| Gala Health | 8.3/10 Best Overall | $149/mo | Highest overall score; brand-name + compounded; all 50 states |
| Wellorithm | 8.3/10 Best Brand Access | $147/mo | Brand-name + compounded on one platform; oral option; 49 states |
| Yucca Health | 7.8/10 Best Value | $146/mo | LegitScript-certified; free UPS 2-Day; 24/7 care team |
| Synergy RX | 7.5/10 Best Support | $199/mo | Highest clinical oversight score (8.5/10); 24/7 dedicated team |
Compare all 13 ranked GLP-1 clinics →
Frequently Asked Questions
Is the semaglutide shortage 2026 still ongoing?
No. The FDA officially removed semaglutide from its Drug Shortages Database in early February 2025. Tirzepatide's shortage ended in October 2024. Both Wegovy and Zepbound are widely available at retail pharmacies nationwide. The semaglutide shortage 2026 is a resolved supply situation — ongoing regulatory activity concerns permanently codifying the end of large-scale 503B compounding, not a new shortage.
Can I still get compounded semaglutide in 2026?
Yes. The shortage designation ending affected large-scale 503B outsourcing facilities. Licensed 503A compounding pharmacies — filling patient-specific prescriptions from licensed clinicians — operate under different legal authority and continue in 2026. Compounded semaglutide is available from $133–$199/month through licensed telehealth clinics.
Why did compounded GLP-1 prices go up in 2025 and 2026?
The 2023–2024 shortage period enabled 503B facilities to produce at industrial scale, briefly driving prices below $100/month. Those facilities have wound down. Licensed 503A pharmacies have always operated per-patient, and their pricing reflects individual-prescription scale. The $133–$299/month range in 2026 reflects market normalization, not price gouging.
Is compounded tirzepatide still available in 2026?
Yes, through the same 503A telehealth model. Tirzepatide's shortage designation ended in October 2024, but 503A pharmacies continue filling individual patient prescriptions in 2026. Prices run $199–$299/month through licensed clinics. The FDA's 2025–2026 enforcement specifically targeted 503B facilities; the 503A individual-prescription pathway continues.
Should I switch to brand-name Wegovy or Zepbound?
It depends on your insurance. Commercially insured patients with qualifying plans and Novo Nordisk's savings card can pay as little as $25/month for Wegovy. Uninsured patients face $1,349/month cash for Wegovy or $399–$549/month for Zepbound via Lilly Direct — still far above compounded alternatives. The right choice depends on your coverage and your priority between cost and the regulatory certainty of an FDA-approved branded product.
Is the proposed FDA semaglutide ban related to the shortage?
Yes — the shortage ending is what triggered the regulatory cascade. The FDA's April 2026 proposed rule to formally exclude semaglutide and tirzepatide from the 503B bulk substances list codifies the enforcement position the agency has held since the February 2025 shortage resolution. Our semaglutide ban explainer covers the proposed rule timeline and what it means for the 503A pathway patients actually use.
Related reading:
- Is Compounded Semaglutide Still Legal in 2026? The Full Legal Background
- Semaglutide Ban: What Happens After the June 29 Deadline?
- How Much Does GLP-1 Weight Loss Cost in 2026?
- Best Oral & Needle-Free GLP-1 Programs in 2026
This article is for informational purposes only and is not legal or medical advice. Regulatory status may change. For personal medical decisions, consult a licensed healthcare provider. Compounded GLP-1 is not FDA-approved.
Affiliate disclosure: This site may earn a commission if you visit a clinic through a link on this page. Commission does not influence our editorial rankings or scores. See our affiliate disclosure.
